Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression-Reference-Cited by-全球学者库

Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression

Published:2019-05-02 Issue: Volume: Page:
ISSN:0143-3334
Container-title:Carcinogenesis
language:en
Short-container-title:

Author:

Li Zhang¹,Shao Chenghao²,Liu Xiaoxiao¹,Lu Xiaojing¹,Jia Xiaona¹,Zheng Xufen¹,Wang Simin¹,Zhu Li³,Li Ke¹,Pang Yuzhi¹,Xie Feifei¹,Lu Yuan⁴,Wang Yuexiang¹^ORCID

Affiliation:

1. CAS Key Laboratory of Tissue Microenvironment and Tumor, SIBS-Changzheng Hospital Joint Center for Translational Medicine, Shanghai Changzheng Hospital, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai, China

2. Department of Pancreatic-Biliary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China

3. Department of General Surgery, PLA General Hospital, Beijing, China

4. Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Funder

National Key R&D Program of China

National Natural Science Foundation of China

Basic Research Project of Shanghai Science and Technology Commission

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

Link